Form 4: Day One Biopharmaceuticals Executive Samuel Blackman Sells 20,000 Shares

Samuel Blackman, Head of R&D at Day One Biopharmaceuticals, sold 20,000 shares of common stock at an average price of $16.0113 on July 16, 2024, according to a Form 4 filing.

Summary

• On July 16, 2024, Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 20,000 shares of common stock.
• The shares were sold at a weighted average price of $16.0113, with individual transactions ranging from $16.00 to $16.04 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2023.
• Following the transaction, Blackman directly owns 1,121,081 shares of Day One Biopharmaceuticals.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan. It's a routine disclosure, but the market reaction will depend on investor interpretation.

Negatives

• The sale of shares by a company executive could be perceived negatively by investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this sale was conducted under a pre-arranged trading plan.

Industry Context

Insider trading activity is closely monitored in the biopharmaceutical industry, as it can provide insights into the perceived value and future prospects of a company. Form 4 filings are a standard part of regulatory compliance for company insiders.

Stakeholder Impact

• The stock sale could potentially influence investor sentiment, depending on how the market interprets the transaction.

Key Dates